Myxomatosis

From WikiMD's WELLNESSPEDIA

Myxomatosis is a disease that primarily affects rabbits, caused by the Myxoma virus. It was first observed in Uruguay in the late 19th century, before spreading to other parts of the world. The disease is highly lethal and has been used as a form of biological control to reduce rabbit populations in areas where they are considered pests.

History[edit]

The Myxoma virus was first discovered in Uruguay in 1896, where it was found to cause a mild disease in its natural hosts, the South American tapeti rabbit (Sylvilagus brasiliensis). The virus was later introduced to Australia and Europe in an attempt to control the populations of the European rabbit (Oryctolagus cuniculus), which had become a significant pest species in these areas.

Transmission[edit]

Myxomatosis is transmitted through direct contact with infected rabbits or through the bite of a vector, such as a mosquito or flea. The virus can survive for a short time in the environment, but is quickly inactivated by heat, drying, and sunlight.

Symptoms[edit]

The symptoms of myxomatosis vary depending on the strain of the virus and the susceptibility of the host. In general, infected rabbits may exhibit swelling and discharge from the eyes and genitals, lethargy, fever, and loss of appetite. In severe cases, the disease can cause blindness, severe skin lesions, and death.

Treatment and control[edit]

There is no specific treatment for myxomatosis. Control measures include vaccination, control of vectors, and quarantine of infected animals. In some countries, the deliberate release of the Myxoma virus as a form of biological control is strictly regulated due to the potential for the virus to evolve and infect non-target species.

See also[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Myxomatosis[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Myxomatosis&oldid=6342903"